Geron at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Geron exhibits at Booth 1929 at ASH 2026 in New Orleans. Its presence centres on myelofibrosis and MDS, where it supports symposia on current and future treatment. It also supports a symposium on applying emerging evidence to real-world care in myeloproliferative neoplasms.
| Organization | ASH 2026 Attendance |
|---|---|
Geron Foster City, CA | |
Biopharmaceutical company marketing imetelstat (RYTELO), a telomerase inhibitor for lower-risk MDS, and studying it in myelofibrosis. | Booth Exhibiting at Booth 1929 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations™: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. Symposium Fri Dec 11 3:00pm–6:00pm MDS in the Modern Era: Getting Ahead of the 8-Ball Moving myelodysplastic syndrome care toward early disease-modifying drugs, with hypomethylating agents for higher-risk disease and wider transplant access. |
Instantly find 20 buyers from Geron
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction